Sign in
Taking people in United StatesNo phase

Looking for stomach outlet valve problems in people with gastroparesis symptoms

Checks how common pyloric sphincter problems are in adults with gastroparesis symptoms.

Key facts

Who runs it
Johns Hopkins Bloomberg School of Public Health
Where
Boston, Louisville, Philadelphia, Scottsdale, and Winston-Salem, United StatesSee the 5 sites
Trial code
Registry title
Pyloric Sphincter Abnormalities in Patients With Gastroparesis Symptoms
Status
Recruiting
People taking part
150 people, planned
Started
13 Jan 2026
Expected to end
15 Apr 2027
Type of study
Observational, 2 groups
Record updated
3 April 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with symptoms of gastroparesis (a slow-emptying stomach), from diabetes or unknown cause. It also takes control participants without these symptoms who are having an upper endoscopy (a camera test of the stomach) for other reasons.

Age
Symptom group: 18 to 85 years. Control group: 18 years or older.
Sex
Men and women can join.
Disease stage
Symptom group: gastroparesis symptoms with a GCSI score of at least 2.0. Gastric emptying can be delayed or normal. Control group: upper stomach symptoms of 1 or less on the GCSI, having endoscopy for diarrhea, GI bleed, iron-deficiency anemia, or weight-loss surgery evaluation.
Earlier treatment
Symptom group: a 4-hour gastric emptying scan within the last 6 months. No new treatments until the study ends. Must stop certain drugs (such as prokinetics, narcotics, laxatives, proton pump inhibitors, cannabinoids, CBD) for 3 days before each visit. Cannot join after surgery on the esophagus, stomach or pylorus, or botulinum toxin injection there.

Main reasons for not taking part

  • Prior surgery on the esophagus, stomach or pylorus, or blockage of the gut
  • Ulcers or varices seen on a prior endoscopy, or other stomach disease that could cause the symptoms
  • Kidney insufficiency, inflammatory bowel disease, current eating disorder, or pregnancy
  • Daily opioid use or use more than 3 days a week
  • Use of GLP1 receptor agonists, SGLT2 drugs, or GIP-GLP combination drugs

The registry criteria, word for word

Show all 30 criteriaShow less

Who can take part

  • Provision of signed and dated informed consent form
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Male or female, aged 18-85
  • Symptoms of gastroparesis, either diabetic or idiopathic etiology
  • Symptoms of gastroparesis with minimum Gastroparesis Cardinal Symptom Index (GCSI) score of 2.0
  • Individual will have had a prior 4-hour gastric emptying scintigraphy test performed for clinical evaluation within the last 6 months. This gastric emptying test would be done for clinical evaluation and is not part of the research study. From these participants with gastroparesis symptoms, we will include those with delayed gastric emptying as well as those with normal gastric emptying
  • Participant must not initiate any new treatments until completion of the study procedures
  • Willingness to:; Stop histamine 2 antagonists, prokinetics (e.g., metoclopramide, erythromycin, domperidone, prucalopride), narcotics, anticholinergics, constipation medications (over the counter laxatives, isotonic polyethylene glycol (PEG) electrolyte preparations (e.g. MiraLax), prescription laxatives (e.g. lubiprostone), proton pump inhibitors, cannabinoids, and cannabidiol (CBD) for 3 days prior to each visit; Abstain from food and water after midnight (at least for 8 hours) before the start of each visit until after the visit
  • Provision of signed and dated informed consent form
  • Male or female, aged 18 or older
  • Undergoing an upper endoscopy for their clinical evaluation of diarrhea, GI bleed, or iron-deficiency anemia, or evaluation for bariatric surgery
  • Do not have upper GI symptoms greater than 1 as assessed by the Gastroparesis Cardinal Symptom Index (GCSI) of PAGI-SYM questionnaire

Who cannot take part

  • Prior gut lumen surgery on the esophagus or the stomach, including Nissen fundoplication
  • Prior surgery on the pylorus (G-POEM, surgical pyloroplasty, surgical pyloromyotomy)
  • Abnormalities seen on a prior upper endoscopy placing patient at increased risk:; Ulcer of the esophagus, stomach, or duodenum; Esophageal varices
  • Females who are pregnant. A urine pregnancy test is routinely obtained on all females immediately prior to endoscopic procedures
  • Prior inflammatory bowel disease, Crohn's
  • Known history of achalasia or esophageal stricture
  • Known history of physiological or mechanical GI obstruction
  • Individuals at risk for prolonging the endoscopy procedure: severe chronic pulmonary disease, severe food retention in the stomach on endoscopy
  • Presence of significant gastric or duodenal pathology that could be expected to cause dysmotility (e.g. significant inflammation, infiltrate disorders etc)
  • Individuals with a history of other chronic disease potentially causative of gastrointestinal symptom
  • Acute or chronic renal insufficiency
  • Current eating disorders
  • Individuals with contraindications for endoscopy, including bleeding abnormalities
  • Allergy to eggs preventing sedation with propofol and/or gastric emptying test
  • History of any esophageal/gastric/pyloric injection of botulinum toxin
  • Use of glucagon-like peptide 1 (GLP1) receptor agonists or Sodium-Glucose Transport Protein 2 (SGLT2); Gastric inhibitory polypeptide (GIP)- glucagon-like peptide (GLP) combo
  • Significant dysphagia
  • Patients on daily opioid use or >3 day/week use

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 85 years old?

Where in United States

  • Massachusetts GeneralBoston, United StatesContact: Nir Bar, MDTaking people
  • University of LouisvilleLouisville, United StatesContact: Bridget Cannon, RNTaking people
  • Temple UniversityPhiladelphia, United StatesContact: Rona T CooperTaking people
  • Mayo Clinic - ArizonaScottsdale, United StatesContact: Guillermo Barahona, PhDTaking people
  • Wake Forest University Health SciencesWinston-Salem, United StatesContact: Baha Moshiree, MDTaking people

About the trial

What the trial wants to find out

The overall objective of this study is to determine if there are pyloric sphincter abnormalities in patients with gastroparesis symptoms and determine how prevalent these abnormalities are using tests to assess the pyloric sphincter - endoluminal functional luminal imaging probe (Endoflip™), water load satiety testing (WLST), and high-resolution cutaneous electrogastrography (HR-EGG) using Gastric Alimetry™ System.

The 2 groups in the trial

  • Symptoms of gastroparesis

    Participants with symptoms of gastroparesis with minimum Gastroparesis Cardinal Symptom Index (GCSI) score of 2.0

  • Control participants

    Participants undergoing endoscopy for evaluation but without gastroparesis symptoms or gastroesophageal reflux symptoms. Score 1.0 or less (≤ 1 ) on the GCSI of Patient Assessment of Upper Gastrointestinal Symptom Severity Index (PAGI-SYM) questionnaire

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Pyloric Sphincter Abnormalities in Patients With Gastroparesis Symptoms
Plain-language title
Looking for stomach outlet valve problems in people with gastroparesis symptomsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Fit questions
Built from NCT04661215, who can take part
Record updated
3 April 2026